NCCN's video: Part 1 - Introduction and Policy Recommendations

Topics Discussed: Welcome and Introductions Robert W. Carlson, MD Chief Executive Officer, National Comprehensive Cancer Network Policy Recommendations from NCCN Working Group Jeff Allen, PhD President & CEO, Friends of Cancer Research Ronald S. Walters, MD, MBA, MHA, MS Associate Head for the Institute for Cancer Care Innovation The University of Texas MD Anderson Cancer Center Policy Summit Overview: As Congress considers revisiting the landmark 21st Century Cures Act, NCCN is engaging experts and gathering perspectives on the successes and challenges of the legislation and its impact on the oncology ecosystem. The June Summit will be conducted as a live webinar and will feature a diverse group of experts who will explore the impact of the 21st Century Cures Act on patients’ access to high-quality cancer care, the implementation of the Cures Act to date, remaining gaps and challenges of the legislation, and a prospective look at Cures 2.0. This free online program was held on June 10, 2020. Supporters: Supported by Adaptive, AmerisourceBergen, Amgen, Astellas, AstraZeneca through its NCCN Corporate Council Membership, BeiGene, Ltd., bluebird bio, Dendreon Pharmaceuticals, Eisai Inc, EMD Serono, Exelixis, Foundation Medicine, Inc., Genentech, GSK, Halozyme, Heron, Incyte Corporation, Janssen Oncology; Pharmaceutical Companies of Johnson & Johnson, Kite, a Gilead Company, an independent educational grant from Merck & Co., Inc., MorphoSys US, Inc., Regeneron Pharmaceuticals, Inc., Sun Pharma Oncology, Takeda, and Verastem Oncology. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. This activity was made possible by Pharmacyclics, an AbbVie Company.